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Objectives
We aimed first to summarise minimal clinically important differences (MCIDs) after total hip 
(THR) or knee replacement (TKR) in health-related quality of life (HRQoL), measured using 
the Short-Form 36 (SF-36). Secondly, we aimed to improve the precision of MCID estimates 
by means of meta-analysis.
Methods
We conducted a systematic review of English and non-English articles using MEDLINE, the 
Cochrane Controlled Trials Register (1960–2011), EMBASE (1991–2011), Web of Science, 
Academic Search Premier and Science Direct. Bibliographies of included studies were 
searched in order to find additional studies. Search terms included MCID or minimal 
clinically important change, THR or TKR and Short-Form 36. We included longitudinal 
studies that estimated MCID of SF-36 after THR or TKR.
Results
Three studies met our inclusion criteria, describing a distinct study population: primary 
THR, primary TKR and revision THR. No synthesis of study results can be given.
Conclusions
Although we found MCIDs in HRQoL after THR or TKR have limited precision and are not 
validated using external criteria, these are still the best known estimates of MCIDs in HRQoL 
after THR and TKR to date. We therefore advise these MCIDs to be used as absolute 
thresholds, but with caution.
Article focus
 We hypothesised that the precision of
minimal clinically important differences
(MCID) estimates could be enhanced by
means of a meta-analysis
Key messages
 Meta-analyses enhance the precision of
an estimate by pooling data from differ-
ent studies
 Meta-analyses are not limited to results
from randomised controlled trials. Any
estimate from any type of study can be
enhanced using the point estimate and its
standard error
Strengths and limitations
 This is the first study that sets out to
enhance the precision of the estimate of a
minimal clinically important difference
 We could not perform a meta-analysis
due to the lack of published MCID esti-
mates
Introduction
Total hip (THR) and knee replacement (TKR)
are effective surgical interventions, which
alleviate pain and improve function and
health-related quality of life (HRQoL) in
patients with end-stage degeneration of the
hip or knee joint, respectively.1 Typically,
studies report the mean improvement in
HRQoL at the population level, which
provides information for the average patient
in a population. However, this information
may not be meaningful for individual
patients encountered in clinical practice, who
will be concerned with the likelihood that
they will experience a meaningful improve-
ment in return for the risk undertaken when
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undergoing an intervention.2 More relevant for the indi-
vidual patient therefore is the minimal clinically impor-
tant difference (MCID), defined as the minimal difference
in scores of an outcome measure that is perceived by
patients as beneficial or harmful.3,4 The MCID enables
patients to be classified as either a responder or a non-
responder to a particular therapy, based on their own
assessment of their pre- and post-operative HRQoL.
Additionally, the MCID allows an estimation of the prob-
ability of a relevant improvement in HRQoL of a particular
therapy.
Expected benefits of treatment must be weighed
against its adverse effects, inconvenience and costs.5
Therefore, there is not necessarily a single MCID value for
any one outcome measure of HRQoL, which can be used
for all applications and patient samples.6 For instance, the
benefits of treatment in patients suffering from end-stage
osteoarthritis are considerably larger for THR and TKR
compared with rehabilitational interventions. On the
other hand, the risk of adverse effects is also considerably
higher. These differences complicate the direct use of
MCIDs in HRQoL as established for rehabilitational inter-
ventions,7 in THR or TKR patients. The use of specific
MCIDs in HRQoL after THR or TKR should be encouraged.
MCIDs can be established using two different methods.
Anchor-based approaches use an external indicator to
assign patients into several groups reflecting different
amounts of change in health status.6 The within-person
global change rating is often used as an anchor, which is
measured using Likert scales, ranging from five to
15 options.6 Positive MCIDs are usually estimated by the
mean difference between pre- and post-operative scores
of patients, who indicate that their condition is ‘some-
what better’; negative MCIDs are usually estimated by
the mean difference between pre- and post-operative
scores of patients who indicate that their condition is
‘somewhat worse’.5,8 Distribution-based methods offer
another approach in the estimation of MCIDs, which
interpret results in terms of the relation between the mag-
nitude of effect and some measure of variability in
results.5 Individual effect size standards are often used to
estimate the MCID, which is defined as the difference
between a patient’s pre- and post-operative HRQoL
scores, normed to the standard deviation of the pre-oper-
ative scores.8 Generally accepted individual effect size
standards are equal to the group effect size standards, as
defined by Cohen.9 Therefore, the MCID is calculated by
multiplying the standard deviation of patients at baseline
by 0.5.
Recently Quintana et al10 and Escobar et al11 have esti-
mated MCIDs for the SF-36 after THR and TKR. However,
these authors have advised against using the found esti-
mates of MCIDs as absolute thresholds, due to the impre-
cision of these estimates caused by small sample sizes.
The precision of an estimate can be enhanced by pooling
results of multiple studies in a meta-analysis. Therefore,
the purpose of our study was to enhance the precision of
the MCIDs after THR and TKR, by means of a systematic
review and meta-analysis.
Materials and Methods
This systematic review was performed in November 2011,
using the PRISMA-Statement (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) as a guideline
in the development of the study protocol and the report
of the current study.12 The inclusion criteria and methods
of analysis were specified in advance and documented in
a protocol.
Information sources and search strategy. Longitudinal
studies that estimate the MCID in HRQol, measured using
the Short-Form 36 (SF-36), after primary or revision THR or
TKR, were eligible for inclusion. No language, publication
date, or publication status restrictions were imposed.
Studies were identified by searching electronic data-
bases. No limits were applied for language and foreign
papers were translated. This search strategy was applied to
PubMed, MEDLINE, Embase, Web of Science, COCHRANE,
ScienceDirect and Academic Search Premier. The search
was run on 8 November 2011. The following search terms
were used in PubMed, and were adapted for the other
databases: (Mcid[tw] OR cid[tw] OR “Minimal clinically
important differences” OR “Minimal clinically important
difference” OR “clinically important differences” OR “clin-
ically important difference” OR MCIC[tw] OR “Minimal
clinically important changes” OR “Minimal clinically
important change” OR “clinically important changes” OR
“clinically important change” OR “Minimal clinical impor-
tant differences” OR “Minimal clinical important differ-
ence” OR “clinical important differences” OR “clinical
important difference” OR “clinical important changes” OR
“minimal detectable change” OR “minimal detectable
changes” OR “minimally detectable change” OR “mean-
ingful changes” OR “meaningful change”) AND (tka[tw]
OR “knee replacement arthroplasty” OR “knee arthro-
plasty” OR “knee replacement” OR “knee prosthesis” OR
tha[tw] OR “hip replacement arthroplasty” OR “hip arthro-
plasty” OR “hip replacement” OR “hip prosthesis” OR
“knee” OR “knees” OR “hip” OR “hips”) AND (“SF36” OR
“SF-36” OR “short form 36” OR “shortform 36”).
Study selection. Two authors (JCK and FRvT) indepen-
dently screened titles and abstracts of the papers resulting
from the database search using predefined eligibility crite-
ria. Papers were considered eligible for inclusion if they met
two criteria; they were to concern primary or revision THR
or TKR and should include an estimate of a MCID. The full
text of all included papers, based on titles and abstracts,
were screened using the same inclusion criteria. Disagree-
ments between reviewers were resolved by consensus.
HRQoL measured using SF-36. The SF-36 consists of
36 items, covering eight domains (physical function, role
physical, bodily pain, general health, vitality, social func-
tion, role emotional, and mental health), for which a
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transformed score is calculated (100 indicating no symp-
toms and 0 indicating extreme symptoms).13
Data collection process and data items. Both authors
extracted the data independently, using a predefined
data extraction form. Areas of disagreement or uncer-
tainty were resolved by consensus. Estimates of MCIDs
were extracted from included studies. For anchor-based
estimates of MCIDs, we extracted the number of patients,
on which the estimate was based, and the standard devi-
ation. For distribution-based estimates, we extracted the
number of patient on which the estimate was based.
Additionally, study characteristics, concerning follow-up
period, sample size, proportion of patients who under-
went joint replacement for osteoarthritis, proportion of
males, mean patient age and proportion lost to follow-
up, were collected.
Risk of bias in individual studies. We assessed the risk of
bias in the included studies through a modified
Newcastle-Ottawa Quality Assessment Scale,14 which
included the following questions: which approach was
used to estimate the MCID? (anchor-based versus distri-
bution-based); was any form of additional validation per-
formed? (yes/no); was the study population
representative of THR or TKR in general? (truly represen-
tative/somewhat representative/selected population/not
enough information given); was the follow-up adequate?
(no loss to follow-up/< 5% lost to follow-up (unlikely to
bias results)/> 5% lost to follow-up (results possibly
biased)). We chose the cut-off point of 5% lost to follow-
up according to Pijls et al,15 who established this thresh-
old for observational studies in orthopaedic literature,
using a Delphi approach to form consensus between a
group of experts in the fields of THR, TKR or evidence-
based medicine.
Summary measures and planned methods of analysis.
The primary outcome measure was the MCID in HRQoL,
measured using SF-36, for primary THR, primary TKR,
revision THR and revision TKR. Whenever possible, esti-
mates of MCIDs were pooled using inverse variance
weighting. 95% confidence intervals (CI) were calculated
for all MCID estimates.
Results
Study selection. The search strategy revealed a total of
126 results (Fig. 1). After removal of duplicate entries,
114 unique papers remained. Screening of titles and
abstracts revealed 29 papers eligible for inclusion.
Further assessment of eligibility, based on full-text
papers, led to the exclusion of 26 papers: two did not
address THR or TKR and 24 presented no estimation of
an MCID. This left three papers, describing three studies,
for further analysis.10,11,16
Records identified through database searching
(n = 126)






Full-text papers assessed for eligibility
(n = 29)



























 No THR/TKR: 2
 No MCID estimated: 24
Fig. 1
Flow-chart of study inclusion (THR, total hip replacement; TKR, total knee replacement; MCID, minimal clinically
important difference).
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Study characteristics. An overview of the study charac-
teristics of all included studies is presented in Table I.
Quintana et al10 describe the MCID in SF-36 after
primary THR at follow-up periods of six months and two
years; Escobar et al11 describe the MCID in SF-36 after
primary TKR at follow-up periods of six months and two
years; and Shi et al16 describe the MCID in SF-36 after
revision THR at a follow-up period of six months
(Table I). All included studies were multi-center studies.
All studies estimated positive MCIDs (i.e. the minimal
difference in scores of the SF-36 that is perceived by
patients as beneficial); no study estimated negative
MCIDs (the minimal difference in scores of an outcome
measure that is perceived by patients as harmful). The
sample for the estimation of the MCIDs was 43 patients
after six months and 33 after two years for Quintana et
al10; 76 after six months and 65 after two years for
Escobar et al11; and 67 after six months for Shi et al16
(Table I). The indication for joint replacement was osteo-
arthritis in all patients of Quintana et al10 and Escobar
et al,11 while Shi et al16 offered no statement of the
indication for joint replacement (Table I). In all studies,
some patients were lost to follow-up.
Risk of bias within studies. An overview of the risk of
bias within studies is presented in Table II. Two studies
used anchor-based approaches to estimate the MCID,10,11
while the other used a distribution-based approach.16 No
study performed any form of additional validation. The
study populations of Quintana et al10 and Escobar et al11
are truly representative of THR and TKR patients in gen-
eral, while Shi et al16 did not provide enough information
to assess the representativeness by leaving out the indica-
tion of joint replacement. All studies lost > 5% of patients
to follow-up, rendering a possibility of biased results.
Synthesis of results. All studies have described a distinct
study population, precluding any meaningful synthesis of
study results. An overview of the results of all individual stud-
ies is presented in Table III and Figures 2 and 3. The MCIDs
are presented with 95% confidence intervals for each of the
SF-36 domains in primary TKR and primary and revision THR
at six months (Fig. 2, Table III)10,11,16 and for primary TKR and
THR at two years post-operatively (Fig. 3, Table III).10,11
Table I. Study characteristics of the three included studies























Escobar et al11 Primary TKR 6 months Multi-centre Positive 
MCID only
423 76 100 25.0 71.6 22.39
Primary TKR 2 years Multi-centre Positive 
MCID only
364 65 100 25.0 71.6 33.21
Quintana et al10 Primary THR 6 months Multi-centre Positive 
MCID only
485 43 100 49.3 69.4 21.86
Primary THR 2 years Multi-centre Positive 
MCID only
310 33 100 49.3 69.4 36.08
Shi et al16 Revision THR 6 months Multi-centre Positive 
MCID only
67 67 n/a 56.7 70.2 16.25










Escobar et al11 Primary TKR 6 months Anchor-based No Truly representative More than 5% lost, 
results possibly biased
Primary TKR 2 years Anchor-based No Truly representative More than 5% lost, 
results possibly biased
Quintana et al10 Primary THR 6 months Anchor-based No Truly representative More than 5% lost, 
results possibly biased
Primary THR 2 years Anchor-based No Truly representative More than 5% lost, 
results possibly biased
Shi et al16 Revision THR 6 months Distribution-based No Description of cohort 
incomplete: no 
statement on indication 
for primary intervention
More than 5% lost, 
results possibly biased
* TKR, total knee replacement; THR, total hip replacement 
† MCID, minimal clinically important difference
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Discussion
We have found one study describing MCIDs in SF-36 after
primary THR,10 one after primary TKR11 and one after revi-
sion THR16; we did not find any studies describing MCIDs
after revision TKR. As all studies have described a distinct
study population, no synthesis of study results can be
given. Therefore, we were unable to improve the preci-
sion of each MCID estimate.
However, in order to visualise the precision of all MCID
estimates, we calculated 95% confidence intervals of all
MCID estimates, which were not presented in the original
studies. These confidence intervals are presented in
Figures 2 and 3.
The findings of this systematic review underline the
need to identify MCIDs for each specific population. As
can be seen from Figures 2 and 3, MCIDs differ both
between SF-36 subscales and patient populations. The
use of a ‘one-size-fits-all’ MCID does not appear justified,
as patients suffering from osteoarthritis of the hip and
knee, which are regarded as similar disease entities, have
different MCIDs in HRQoL.17-19 In order to study patient-
relevant improvements in HRQoL at the individual level in
revision TKR patients, MCIDs need to be established in
this particular population as well.
Limitations of the included studies include imprecision
as a result of small sample sizes, the lack of validation of
the MCID estimates and the rates of loss to follow-up.
Anchor-based approaches in particular suffer from impre-
cision due to small sample sizes, as this approach uses
only a part of all data to estimate the MCID. A precise esti-
mation of the MCID is further hampered by the clinical
success of joint replacement: typically, one expects a
large effect of THR or TKR.20 The group sizes of patients
who indicate that their condition has “somewhat
improved” are therefore expected to be small, which con-
tributes to an imprecise estimation of MCIDs. Unfortu-
nately, there are only two ways to improve the precision
of anchor-based MCID estimates: one can either perform
larger studies, or pool study results in a meta-analysis. To
date, the only studies that have established anchor-based
MCIDs in HRQoL after primary THR or TKR were those of
Quintana et al10 and Escobar et al.11 More research is
required to improve the precision of MCIDs in HRQoL.
Estimates with higher precision are generated by distribu-
tion-based approaches, which use data from the entire
population to estimate the MCID. However, these
approaches are criticised for the arbitrariness of the indi-
vidual effect size standards.5
A strongly recommended method of determining
MCIDs is by triangulation of multiple approaches.6 None
of the included studies has applied any form of additional
validation, such as secondary anchor questions; all used a
Table III. Minimal clinically important differences (MCIDs) in Short-Form 36 (SF-36)
domains after primary and revision total hip replacement (THR) and primary total knee
replacement (TKR)
MCID (95% confidence interval)
SF-36 domain At six months At two years
Primary THR Physical functioning 20.40 (14.4 to 26.4) 8.29 (-1.8 to 18.4)
Role physical 10.78 (1.5 to 20.0) 11.00 (-1.3 to 23.3)
Bodily pain 14.67 (6.8 to 22.6) 18.34 (9.1 to 27.6)
General health 0.40 (-5.2 to 6.0) -6.37 (-10.9 to -1.9)
Vitality 10.14 (3.1 to 17.2) 14.51 (6.4 to 22.6)
Social functioning 8.63 (0.9 to 16.4) 17.97 (7.8 to 28.1)
Role emotional -6.45 (-24.5 to 11.6) 20.83 (-0.6 to 42.3)
Mental health 8.99 (2.3 to 15.7) 16.15 (9.0 to 23.3)
Primary TKR Physical functioning 11.57 (6.5 to 16.7) 11.07 (5.8 to 16.3)
Role physical 11.69 (3.8 to 19.6) 13.16 (3.5 to 22.8)
Bodily pain 16.86 (9.7 to 24.0) 6.69 (-0.4 to 13.8)
General health 0.85 (-3.2 to 4.9) -7.30 (-11.3 to -3.3)
Vitality 3.86 (-1.7 to 9.4) 3.44 (-2.2 to 9.1)
Social functioning 11.66 (3.7 to 19.6) 6.15 (-1.7 to 14.0)
Role emotional 7.65 (-4.5 to 19.8) 2.42 (-9.2 to 14.1)
Mental health -0.32 (-5.5 to 4.9) 4.02 (-1.7 to 9.7)
Revision THR Physical functioning 3.25 (2.8 to 3.9) -
Role physical 4.78 (4.1 to 5.8) -
Bodily pain 14.91 (12.7 to 18.0) -
General health 14.12 (12.1 to 17.0) -
Vitality 22.81 (19.5 to 27.5) -
Social functioning 15.83 (13.5 to 19.1) -
Role emotional 19.98 (17.1 to 24.1) -
Mental health 12.37 (10.6 to 14.9) -
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single approach. Besides a limited precision, caused by
small group sizes, the accuracy of the MCID estimates
might be limited as well due to this lack of additional val-
idation.21 Therefore, further research is needed to provide
external validation of the established MCIDs in HRQoL.
However, until further research is performed, the MCID
estimates of these three studies10,11,16 are the best avail-
able estimates. Cautious use of these estimates should be
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Graph showing the minimal clinically important differences (MCIDs) in the domains of the Short-Form 36 (SF-36) at six
months after primary total hip (THR)10 and total knee replacement (TKR)11 and revision THR.16 The size of the coloured cir-
cles represents the sample sizes used to estimate the MCID, and the error bars denote the 95% confidence intervals (PF,
physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emo-
tional; MH, mental health).
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Graph showing the minimal clinically important differences (MCIDs) in the domains of the Short-Form 36 (SF-36) at two
years after primary total hip (THR)10 and total knee replacement (TKR).11 The size of the coloured circles represents the sam-
ple sizes used to estimate the MCID, and the error bars denote the 95% confidence intervals (PF, physical functioning; RP,
role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health).
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encouraged in order to study improvement in HRQoL at
the individual level, the most relevant outcome measure
for individual patients encountered in clinical practice.
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